Page last updated: 2024-11-09

pyrantel

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pyrantel: A depolarizing neuromuscular-blocking agent, that causes persistent nicotinic activation resulting in spastic paralysis of susceptible nematodes. It is a drug of second-choice after benzimidazoles for treatment of ascariasis, hookworm, and pinworm infections, being effective after a single dose. (From Smith and Reynard, Textbook of Pharmacology, 1992, p920) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pyrantel : A carboxamidine that is 1,4,5,6-tetrahydropyrimidine that is substituted at position 1 by a methyl group and at position 2 by an (E)-2-(2-thienyl)vinyl group. It is used, particularly as the embonate [4,4'-methylenebis(3-hydroxy-2-naphthoate)] salt, as an anthelmintic that is effective against intestinal nematodes including threadworms, roundworms and hookworms, and is included in the WHO 'Model List of Essential Medicines'. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID708857
CHEMBL ID1626223
CHEBI ID8654
CHEBI ID94685
SCHEMBL ID164730
MeSH IDM0018221

Synonyms (77)

Synonym
pirantel [inn-spanish]
pyrantelum [inn-latin]
pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)ethenyl)-, (e)-
pyrequan
hsdb 3252
pyrantel [inn:ban]
e-1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)pyrimidine
pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)-, (e)-
pirantele [dcit]
strongid
einecs 239-774-1
BRD-K20672254-046-02-1
1-methyl-2-[(e)-2-(2-thienyl)ethenyl]-1,4,5,6-tetrahydropyrimidine
15686-83-6
C07409
pyrantel
NCGC00174007-02
NCGC00174007-01
HMS1541D15
pyrantel (inn)
konvermex (tn)
D08451
1-methyl-2-[(e)-2-thiophen-2-ylethenyl]-5,6-dihydro-4h-pyrimidine
1-methyl-2-(2-thiophen-2-ylethenyl)-5,6-dihydro-4h-pyrimidine
1-methyl-2-[(e)-2-(thiophen-2-yl)ethenyl]-1,4,5,6-tetrahydropyrimidine
STK676402
AKOS005594318
pirantele
pirantel
pin-x
unii-4qih0n49e7
pyrantelum
4qih0n49e7 ,
pyrantel [hsdb]
pyrantel [who-dd]
konvermex
pyrantel [vandf]
pyrantel [inn]
pyrantel [mi]
pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)ethenyl)-
BRD-K63072637-046-01-2
SCHEMBL164730
CHEMBL1626223
chebi:8654 ,
AB00053538-07
1-methyl-2-[(e)-2-(2-thienyl)vinyl]-1,4,5,6-tetrahydropyrimidine
1-methyl-2-[(e)-2-(2-thienyl)vinyl]-5,6-dihydro-4h-pyrimidine
smr004703508
MLS006011881
1-methyl-2-[(e)-2-(2-thienyl)ethenyl]-1,4,5,6-tetrahydropyrimidine #
pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)ethenyl]-
YSAUAVHXTIETRK-AATRIKPKSA-N
(e)-1-methyl-2-(2-(thiophen-2-yl)vinyl)-1,4,5,6-tetrahydropyrimidine
AB00053538_08
DTXSID5023538 ,
SR-01000802778-4
sr-01000802778
CHEBI:94685
1,4,5,6-tetrahydro-1-methyl-2-[(1e)-2-(2-thienyl)ethenyl]-pyrimidine
DB11156
Q426897
(z)-1-methyl-2-(2-(thiophen-2-yl)vinyl)-1,4,5,6-tetrahydropyrimidine
pyrantel-pamoate
5686-02-2
1-methyl-2-(2-(thiophen-2-yl)vinyl)-1,4,5,6-tetrahydropyrimidine
1,4,5,6-tetrahydro-1-methyl-2-[(e)-2-(2-thienyl)vinyl]pyrimidine
A906579
CS-0013762
HY-12641A
EN300-8684101
pyrantelum (inn-latin)
e-1,4,5,6-tetrahydro-1-methyl-2-
pin-rid
p02cc01
1-methyl-2-((e)-2-(2-thienyl)vinyl)-1,4,5,6-tetrahydropyrimidine
dtxcid403538
pirantel (inn-spanish)

Research Excerpts

Overview

Pyrantel is an anthelmintic which acts as an agonist of nicotinic receptors (AChRs) of nematodes. It exerts its therapeutic effects by depolarizing their muscle membranes.

ExcerptReferenceRelevance
"Pyrantel is an anthelmintic which acts as an agonist of nicotinic receptors (AChRs) of nematodes and exerts its therapeutic effects by depolarizing their muscle membranes. "( The anthelmintic pyrantel acts as a low efficacious agonist and an open-channel blocker of mammalian acetylcholine receptors.
Bouzat, C; De Rosa, MJ; Rayes, D; Spitzmaul, G, 2001
)
2.09

Effects

ExcerptReferenceRelevance
"Pyrantel pamoate has a wider applicability for the poorer patients in spite of the fact that it is ineffective against trichurids and S."( Mebendazole and pyrantel pamoate as broad-spectrum anthelmintics.
Chowdhury, NA; Islam, N, 1976
)
1.32
"Pyrantel pamoate has a wider applicability for the poorer patients in spite of the fact that it is ineffective against trichurids and S."( Mebendazole and pyrantel pamoate as broad-spectrum anthelmintics.
Chowdhury, NA; Islam, N, 1976
)
1.32

Treatment

Treatment with pyrantel at 100 mg kg-1 completely eliminated worms of both species. Doses of 25-50 mgkg-1 were > 90% effective in clearing hookworm infections.

ExcerptReferenceRelevance
"Treatment with pyrantel at 100 mg kg-1 completely eliminated worms of both species and doses of 25-50 mg kg-1 were > 90% effective."( Sensitivity to ivermectin and pyrantel of Ancylostoma ceylanicum and Necator americanus.
Behnke, JM; Garside, P; Rose, R, 1993
)
0.91
"Treatment with pyrantel pamoate in the feed at the concentration of 0.2% given 7 days before inoculation and 5 days after inoculation also protected mice from migrations throughout the 55-day experiment."( Baylisascaris procyonis for testing anthelmintics against migratory ascarids.
Lindquist, WD, 1978
)
0.6
"Treatment with pyrantel in this herd also indicated cross-resistance to this drug."( Resistance to levamisole and cross-resistance between pyrantel and levamisole in Oesophagostomum quadrispinulatum and Oesophagostomum dentatum of pigs.
Bjørn, H; Nansen, P; Roepstorff, A; Waller, PJ, 1990
)
0.87
"Treatment with pyrantel pamoate was estimated to be 91% effective in clearing hookworm infections."( An investigation of hookworm infection and reinfection following mass anthelmintic treatment in the south Indian fishing community of Vairavankuppam.
Anderson, RM; Elkins, DB; Haswell-Elkins, MR; Manjula, K; Michael, E, 1988
)
0.61

Toxicity

ExcerptReferenceRelevance
" Adverse effects were not observed in young kittens following administration of the high dose of pyrantel pamoate."( Evaluation of the efficacy and safety of two formulations of pyrantel pamoate in cats.
DeNovo, RC; Reinemeyer, CR, 1990
)
0.74
" These studies have shown that monthly topical administration of selamectin is safe and highly effective in the treatment of naturally acquired ascarid and hookworm infections in cats."( Efficacy and safety of selamectin against gastrointestinal nematodes in cats presented as veterinary patients.
Benchaoui, HA; Boy, MG; Clemence, RG; Jernigan, AD; Rowan, TG; Six, RH; Smith, DG; Sture, GH; Thomas, CA; Watson, P, 2000
)
0.31
"Simparica Trio™ administered orally once monthly for two consecutive treatments was safe and effective against natural flea infestations and substantially improved clinical signs associated with FAD in client-owned dogs in a field study conducted in the USA."( Safety and efficacy of a novel oral chewable combination tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against natural flea infestations in client-owned dogs in the USA.
Inskeep, T; Kryda, K; Mahabir, SP; Rugg, J, 2020
)
0.77

Compound-Compound Interactions

ExcerptReferenceRelevance
" albendazole and pyrantel, making it a good candidate for further studies on its use in drug combination therapy of STH infections."( Nitazoxanide: nematicidal mode of action and drug combination studies.
Aroian, RV; Ellis, BL; Hu, Y; Somvanshi, VS, 2014
)
0.74

Dosage Studied

Pyrantel pamoate at dosage of 10 mg per kilogramme body weight was given to each villager at 4-6 weeks intervals for three times. In the controlled-critical study, pigs naturally infected with Oesophagostomum dentatum were either not treated or were treated with pyrantels citrate or pyrants tartrate.

ExcerptRelevanceReference
"Pyrantel pamoate at dosage of 10 mg per kilogramme body weight was given to each villager at 4-6 weeks intervals for three times."( Control trial of soil-transmitted helminthic infections with pyrantel pamoate.
Bhaibulaya, M; Harinasuta, C; Hongsuwan, S; Indra-Ngarm, S; Pahuchon, W; Punnavutti, V; Vajrasthira, S; Yamput, S, 1977
)
1.94
" Another strain (VJ) was isolated from another commercial pig herd, which was dosed with pyrantel citrate four times a year for at least 8 years."( Resistance to levamisole and cross-resistance between pyrantel and levamisole in Oesophagostomum quadrispinulatum and Oesophagostomum dentatum of pigs.
Bjørn, H; Nansen, P; Roepstorff, A; Waller, PJ, 1990
)
0.75
" Three groups of 8 cats received either no medication (controls) or pyrantel pamoate in paste or granule formulations at a dosage of 20 mg/kg of body weight."( Evaluation of the efficacy and safety of two formulations of pyrantel pamoate in cats.
DeNovo, RC; Reinemeyer, CR, 1990
)
0.76
" Relative potencies of the drugs were determined from dose-response relationships and the rank order of effectiveness was as follows: carbachol much greater than levamisole greater than pyrantel greater than morantel."( Actions of potent cholinergic anthelmintics (morantel, pyrantel and levamisole) on an identified insect neurone reveal pharmacological differences between nematode and insect acetylcholine receptors.
Gration, KA; Harrow, ID; Pinnock, RD; Sattelle, DB, 1988
)
0.71
"Hamsters infected with laboratory-adapted preadult Necator americanus were dosed with 6 reference anthelmintics."( Response of preadult Necator americanus to some known anthelmintics in hamsters.
Bose, S; Deb, BN; Dhage, KR; Rajasekariah, GR, 1986
)
0.27
" In the controlled-critical study, pigs naturally infected with Oesophagostomum dentatum were either not treated or were treated with pyrantel citrate or pyrantel tartrate at a dosage of 510 mg of free pyrantel base/kg of feed."( Relative efficacies of pyrantel tartrate and pyrantel citrate against Oesophagostomum sp in swine.
Brauer, MA; Corwin, RM; Pratt, SE, 1981
)
0.78
" Oral administration of dichlorvos (60 mg/kg, 3 times the anthelmintic dosage level) 1 hour before levamisole injection lowered blood cholinesterase activity to approximately 60% that of the controls, but did not change the LD50 of levamisole."( Drug interactions of levamisole with pyrantel tartrate and dichlorvos in pigs.
Hsu, WH, 1981
)
0.54
" Animals remained with their owners and were dosed six times, at monthly intervals according to body weight."( The prevention of Dirofilaria repens infection with ivermectin/pyrantel chewables.
Pollmeier, M; Pollono, F; Rossi, L, 1998
)
0.54
" Unit doses of selamectin (providing a minimum dosage of 6mgkg(-1)) were administered topically to the skin in a single spot at monthly intervals."( Efficacy and safety of selamectin against gastrointestinal nematodes in cats presented as veterinary patients.
Benchaoui, HA; Boy, MG; Clemence, RG; Jernigan, AD; Rowan, TG; Six, RH; Smith, DG; Sture, GH; Thomas, CA; Watson, P, 2000
)
0.31
" Additionally, in the field study no dog tested positive for adult heartworm infection when dosed with the combination product monthly for 11 months, while two dogs treated with Heartgard® Plus tested positive."( Laboratory and field studies to investigate the efficacy of a novel, orally administered combination product containing moxidectin, sarolaner and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs.
Chapin, S; Cundiff, B; Holzmer, SJ; Inskeep, T; Kryda, K; Maeder, SJ; Mahabir, SP; McCall, JW; McTier, TL; Myers, M; Pullins, A; Rugg, J; Six, RH; Ulrich, M; Walsh, KF, 2019
)
0.71
" Six laboratory studies were conducted to support dosage selection and efficacy confirmation of a novel combination of sarolaner, moxidectin and pyrantel against four tick species that commonly infest dogs in Europe."( Efficacy of a novel chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against four common tick species infesting dogs in Europe.
Becskei, C; Liebenberg, J; Mahabir, SP; Thys, M, 2020
)
0.99
"2 mg/kg sarolaner was the lowest dosage evaluated that provided > 90% efficacy for at least 28 days and therefore was selected as the dosage to provide tick control for at least one month following a single oral treatment."( Efficacy of a novel chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against four common tick species infesting dogs in Europe.
Becskei, C; Liebenberg, J; Mahabir, SP; Thys, M, 2020
)
0.79
" The initial study (Study 1) determined the efficacious dosage of moxidectin in the combination product by evaluating three different dose levels, and two follow-up studies (Studies 2 and 3) confirmed the efficacy of the selected moxidectin dose."( Efficacy of orally administered combination of moxidectin, sarolaner and pyrantel (Simparica Trio™) for the prevention of experimental Angiostrongylus vasorum infection in dogs.
Becskei, C; Doherty, P; Mahabir, SP; Thys, M, 2020
)
0.79
" Timing of dosing relative to infection allowed for efficacy to be evaluated against the immature adult (L5) stage."( Efficacy of orally administered combination of moxidectin, sarolaner and pyrantel (Simparica Trio™) for the prevention of experimental Angiostrongylus vasorum infection in dogs.
Becskei, C; Doherty, P; Mahabir, SP; Thys, M, 2020
)
0.79
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antinematodal drugA substance used in the treatment or control of nematode infestations.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
thiophenesCompounds containing at least one thiophene ring.
carboxamidineCompounds having the structure RC(=NR)NR2. The term is used as a suffix in systematic nomenclature to denote the -C(=NH)NH2 group including its carbon atom.
1,4,5,6-tetrahydropyrimidinesAny tetrahydropyrimidine in which the double bond is between positions 1 and 2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (320)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990166 (51.88)18.7374
1990's40 (12.50)18.2507
2000's48 (15.00)29.6817
2010's41 (12.81)24.3611
2020's25 (7.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.38 (24.57)
Research Supply Index6.05 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index170.84 (26.88)
Search Engine Supply Index3.94 (0.95)

This Compound (52.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials54 (14.67%)5.53%
Reviews13 (3.53%)6.00%
Case Studies8 (2.17%)4.05%
Observational0 (0.00%)0.25%
Other293 (79.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
EXercise as TReatment for osteoArthritis [NCT03215602]90 participants (Actual)Interventional2017-07-18Completed
Randomized Controlled Trial of Exercise Therapy in Combination With Central Nervous System-targeted Treatment Compared With Exercise Therapy Alone for Treatment of People With Knee Osteoarthritis [NCT03681613]104 participants (Anticipated)Interventional2019-01-07Recruiting
The Efficacy of 5 Anthelmintic Regimes Against T. Trichiura Infections in Schoolchildren in Jimma, Ethiopia [NCT01327469]Phase 42,250 participants (Actual)Interventional2010-12-31Completed
Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon [NCT04326868]Phase 4255 participants (Actual)Interventional2019-11-11Completed
Different Drug Combinations Against Hookworm Infection in School-aged Children in the Lao People's Democratic Republic, a Single Blind, Randomised Controlled Trial [NCT03278431]Phase 4420 participants (Actual)Interventional2017-09-27Completed
Stunting and Bangladesh Environmental Enteric Dysfunction Study [NCT02812615]1,575 participants (Anticipated)Interventional2016-07-16Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]